A considerable roadblock in the successful triaging of new therapeutics for liver disease and metabolic related diseases is the lack of translatability between preclinical models and the clinic.

In this white paper you will discover how human induced pluripotent stem cell derived hepatocyte-like cells (HLCs) have the potential to act as an ideal model for the study of liver diseases, combining the expansion capacity and phenotypic stability of hepatoma cell lines with the functionality and normal karyotype of primary hepatocytes. Within the white paper you will also learn more about DefiniGEN’s iPSC-derived HLC platform which is capable of screening candidate therapeutics with high accuracy and reproducibility.